Could Amgen's Xgeva boost immunotherapy in breast cancer?

Amgen’s osteoporosis drug denosumab is approved as Xgeva for the prevention and treatment of some bone metastases in cancer. But could the drug’s mechanism of action help breast cancer patients respond to immunotherapy drugs that typically don’t work well in those tumors?